Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126417671 | 12641767 | 1 | I | 20160804 | 20160810 | 20160810 | EXP | CA-009507513-1608CAN003808 | MERCK | 0.00 | F | Y | 0.00000 | 20160810 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126417671 | 12641767 | 1 | PS | TEMODAL | TEMOZOLOMIDE | 1 | Oral | 295 MG, OD 5 DAYS PER 28 DAYS (STRENGTH: 250 MG, 5 MG, 20 MG) | 21029 | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126417671 | 12641767 | 1 | Glioblastoma multiforme |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126417671 | 12641767 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126417671 | 12641767 | Neoplasm recurrence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126417671 | 12641767 | 1 | 201509 | 0 |